Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Drug Class
3.2. Market snippet by Indication
3.3. Market snippet by Distribution Channel
3.4. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Frontotemporal Disorders
4.1.1.2. Increasing Funding by Government & Non-Government Organizations
4.1.2. Restraints:
4.1.2.1. High Cost of treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Epidemiology
5.3. Pipeline Analysis
5.4. Supply Chain Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Unmet Needs
5.8. COVID-19 Impact Analysis
6. By Drug Class
6.1. Introduction
6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
6.3. Market Attractiveness Index, By Drug Class Segment
6.3.1. Cognitive Enhancers*
6.3.1.1. Introduction
6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
6.3.2. Antipsychotics
6.3.2.1. Aripiprazole
6.3.2.2. Paliperidone
6.3.2.3. Olanzepine
6.3.2.4. Risperidone
6.3.2.5. Quetiapine
6.3.2.6. Ziprasidone
6.3.3. Antidepressants
6.3.3.1. Bupropion
6.3.3.2. Fluvoxamine
6.3.3.3. Citalopram
6.3.3.4. Fluoxetine
6.3.3.5. Mitrazepine
6.3.3.6. Paroxetine
6.3.3.7. Sertraline
6.3.4. CNS stimulants
6.3.5. Others
7. By Indication
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
7.3. Market Attractiveness Index, By Indication Segment
7.3.1. Behaviour Variants Frontotemporal Dementia. (BFTD)*
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.2. Primary Progressive Aphasia (PPA)
7.3.2.1. Semantic PPA
7.3.2.2. Agrammatic PPA
7.3.2.3. Logopenic PPA
7.3.3. Motor Decline
7.3.3.1. Corticobasal syndrome (CBS)
7.3.3.2. Progressive supranuclear palsy (PSP)
8. By Distribution Channel
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
8.3. Market Attractiveness Index, By Distribution Channel Segment
8.3.1. Hospital Pharmacies*
8.3.1.1. Introduction
8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.3.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. The U.K.
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. Australia
9.5.6.5. Rest of Asia Pacific
9.6. The Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Apotex Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Johnson & Johnson
11.3. Auro Pharma
11.4. Pfizer Inc.
11.5. Teva Pharmaceuticals USA, Inc.
11.6. AstraZeneca plc.
11.7. Mylan N.V.
11.8. Sanofi S.A.
11.9. Valeant Pharmaceutical International
11.10. Eli Lilly and Company (LIST NOT EXHAUSTIVE)
12. DataM Intelligence
12.1. Appendix
12.2. About Us and Services
12.3. Contact Us